CRIS
Permanent URI for this communityhttps://investigadores.udd.cl/handle/123456789/1
Browse
13 results
Search Results
Now showing 1 - 10 of 13
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Fighting resistance with redundancy: a path forward for treating antimicrobial-resistant infections?(American Society for Microbiology, 2025-04-02); Scopus© Citations 2 2 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Andean medicinal plants and their secondary metabolites: Connections between Aymara traditional medicine and modern pharmacology(Elsevier BV, 2025-03); Scopus© Citations 6 2 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Copper-Modified Cellulose Paper: A Comparative Study of How Antimicrobial Activity Is Affected by Particle Size and Testing Standards(MDPI AG, 2025-01-08); Viviana BenavidesThis study aims to provide evidence that when testing cellulose paper modified with copper particles (CuPs), the particle size and the analysis method influence the antimicrobial activity observed by this material. Commercial CuPs of nanometric size (2.7 nm, CuNPs) and micrometric size (2.5 µm, CuMPs) were used to modify cellulose paper sheets. CuPs were incorporated during the pulp disintegration phase (stage 1) of the sheet formation process, according to the ISO 5269-1:2005 standard. Modified paper sheets retained 16% and 14% of CuNPs and CuMPs, respectively. Additionally, CuPs were distributed randomly on the fiber surfaces, often forming aggregates. Finally, the antimicrobial activity of the modified paper sheets was evaluated using ISO 20645:2004 and ISO 20743:2013. The results showed that the antimicrobial activity assessed using each standard method is conditioned by the mechanism of action of the CuPs and, therefore, by their size. It was concluded that ISO 20645:2004 is suitable for evaluating the antibacterial effect of paper/CuNPs, as nanoparticles diffuse from the paper and are released into the culture medium. In contrast, ISO 20743:2013 can be used for both CuNP- and CuMP-based paper, as it evaluates the antibacterial effect based on the direct interaction between the copper particle and the bacteria.Scopus© Citations 2 14 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Editorial: Immune response to gram-negative bacteria in the lungs(2024); - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Spent coffee grounds extract: antimicrobial activity against Paenibacillus larvae and its effect on the expression of antimicrobial peptides in Apis mellifera(2023)1Scopus© Citations 4 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Highly active antiretroviral therapy discontinuation time is associated with therapeutic failure among human immunodeficiency virus (<scp>HIV</scp>)‐infected immigrant adults: A cohort study from a Peruvian referral hospital during the Venezuelan exodus(2023); Alfonso J. Rodriguez‐Morales<jats:title>Abstract</jats:title><jats:sec><jats:title>Objective</jats:title><jats:p>To evaluate the association between Highly Active Antiretroviral Therapy (HAART) discontinuation time and therapeutic failure (TF) in Venezuelan immigrants with HIV that restart HAART.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We carried out a retrospective cohort study in a large hospital in Peru. We included Venezuelan immigrants who restarted HAART and were followed over at least 6 months. The primary outcome was TF. Secondary outcomes were immunologic (IF), virologic (VF) and clinical (CF) failures. The exposure variable was HAART discontinuation, categorised as no discontinuation, less than 6 months, and 6 months or more. We applied generalised linear models Poisson family with robust standard errors to calculate crude (cRR) and adjusted (aRR) relative risks by statistical and epidemiological criteria.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>We included 294 patients, 97.2% were males, and the median age was 32 years. Out of all the patients, 32.7% discontinued HAART for less than 6 months, 15.0% discontinued for more than 6 months and the remaining 52.3% did not discontinue. The cumulative incidence of TF was 27.9%, 24.5% in VF, 6.0% in IF and 6.0% in CF. Compared with non‐discontinued HAART patients, the discontinuation for less than 6 months (aRR = 1.98 [95% CI: 1.27<jats:bold>–</jats:bold>3.09]) and from 6 months to more (aRR = 3.17 [95% CI: 2.02<jats:bold>–</jats:bold>4.95]) increased the risk of TF. Likewise, treatment discontinuation of up to 6 months (aRR = 2.32 [95% CI: 1.40<jats:bold>–</jats:bold>3.84]) and from 6 months to more (aRR = 3.93 [95% CI: 2.39<jats:bold>–</jats:bold>6.45]) increased the risk of VF.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>HAART discontinuation increases the probability of TF and VF in Venezuelan immigrants.</jats:p></jats:sec>10Scopus© Citations 2 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, β-Cyclodextrin Nanosponges Inclusion Compounds Associated with Silver Nanoparticles to Increase the Antimicrobial Activity of Quercetin(2023)Scopus© Citations 7 1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Review on Generation and Characterization of Copper Particles and Copper Composites Prepared by Mechanical Milling on a Lab-Scale(2023)3Scopus© Citations 7 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Antimicrobial Susceptibility Testing for Enterococci(2022); Cesar A. Arias<jats:p>Enterococci are major, recalcitrant nosocomial pathogens with a wide repertoire of intrinsic and acquired resistance determinants and the potential of developing resistance to all clinically available antimicrobials. As such, multidrug-resistant enterococci are considered a serious public health threat.</jats:p>1Scopus© Citations 57 1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Real-World Performance of Susceptibility Testing for Ceftolozane/Tazobactam against Non-Carbapenemase-Producing Carbapenem-Resistant Pseudomonas aeruginosa(2022); 19Scopus© Citations 2